ReviewWorld journal of virology2026
Major histocompatibility complex class I chain-related A and B molecules and their potential role in virus-associated cancers.
Review in World journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections with certain viruses are strong risk factors for specific cancers. The human major histocompatibility complex class I chain-related genes A (MICA) and B (MICB) are polymorphic, non-classical major histocompatibility complex class I genes located within the human leukocyte antigen region. Polymorphisms in these genes have been associated with susceptibility and outcomes of several virus-associated cancers. The underlying mechanisms involve modulation of natural killer cell- and CD8+ T cell-mediated cytotoxicity by disrupting the natural killer group 2-member D-MICA/B axis. The resulting soluble forms of both MICA and MICB have recently gained attention as potential predictive biomarkers for virus-induced malignancies and disease severity. Therapeutic strategies targeting this axis show considerable promise. This minireview summarizes the genetics and biology of MICA and MICB, highlighting their emerging importance in the pathogenesis of virus-associated cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.